Literature DB >> 2123470

A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy.

W C Nichols1, R E Gregg, H B Brewer, M D Benson.   

Abstract

Immunoblotting of isoelectric focusing gels of plasma and direct genomic DNA sequencing have been used to characterize a mutation in apolipoprotein A-I associated with the familial amyloidotic polyneuropathy originally described by Van Allen in an Iowa kindred. An arginine for glycine substitution in apolipoprotein A-I identified in the proband's amyloid fibrils was determined to be the result of a mutation of guanine to cytosine in the apolipoprotein A-I gene at the position corresponding to the first base of codon 26. Direct sequencing of genomic DNA of three affected individuals who died in the 1960s confirmed the inheritance of the disorder. Immunoblot analysis detected the variant apolipoprotein A-I in the proband's plasma and in several at-risk members of the kindred. In addition, allele-specific amplification by the polymerase chain reaction was used to detect carriers of the variant gene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123470     DOI: 10.1016/0888-7543(90)90288-6

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  40 in total

1.  Primary biliary cirrhosis and systemic amyloidosis, a new association.

Authors:  Hector Rodriguez-Luna; Hugo E Vargas; James Williams; Giovanni De Petris; Jorge Rakela; David D Douglas
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 2.  Inherited amyloidosis.

Authors:  M D Benson
Journal:  J Med Genet       Date:  1991-02       Impact factor: 6.318

Review 3.  A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy.

Authors:  M T Walsh
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

4.  Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17.

Authors:  J R Murrell; D Koller; T Foroud; M Goedert; M G Spillantini; H J Edenberg; M R Farlow; B Ghetti
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

5.  Cellular interaction and cytotoxicity of the iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate.

Authors:  Kaori Kuwabara; Kazuchika Nishitsuji; Kenji Uchimura; Shang-Cheng Hung; Makoto Mizuguchi; Hiroyuki Nakajima; Shiho Mikawa; Norihiro Kobayashi; Hiroyuki Saito; Naomi Sakashita
Journal:  J Biol Chem       Date:  2015-08-19       Impact factor: 5.157

6.  Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis.

Authors:  M M de Sousa; C Vital; D Ostler; R Fernandes; J Pouget-Abadie; D Carles; M J Saraiva
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

7.  RFLP analysis for APP 717 mutations associated with Alzheimer's disease.

Authors:  S R Zeldenrust; J Murrell; M Farlow; B Ghetti; A D Roses; M D Benson
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

8.  Retrospective molecular detection of Transthyretin Met 111 mutation in a Danish kindred with familial amyloid cardiomyopathy, using DNA from formalin-fixed and paraffin-embedded tissues.

Authors:  B Y Nordvåg; I Ranløv; H M Riise; G Husby; M R el-Gewely
Journal:  Hum Genet       Date:  1993-10-01       Impact factor: 4.132

9.  Analysis of the prion protein gene in thalamic dementia.

Authors:  R B Petersen; M Tabaton; L Berg; B Schrank; R M Torack; S Leal; J Julien; C Vital; B Deleplanque; W W Pendlebury
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

10.  Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils.

Authors:  Tatsumi Korenaga; Xiaoying Fu; Yanming Xing; Takatoshi Matsusita; Kazunao Kuramoto; Seigo Syumiya; Kazuhiro Hasegawa; Hironobu Naiki; Masaki Ueno; Tokuhiro Ishihara; Masanori Hosokawa; Masayuki Mori; Keiichi Higuchi
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.